Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach

Tomiyasu Arisawa, Tomomitsu Tahara, Tomoyuki Shibata, Mitsuo Nagasaka, Masakatsu Nakamura, Yoshio Kamiya, Hiroshi Fujita, Tamaki Takagi, Shin Hasegawa, Fang Yu Wang, Ichiro Hirata, Hiroshi Nakano

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and Aim: Trypsin acting at protease-activated receptor 2 (PAR2) contributes to a progression of malignant tumors. An abnormal DNA methylation has been recognized as an important molecular mechanism for the genesis of various types of cancers. We attempted to clarify the relationship between the promoter methylation of PAR2 and gastric cancer. Method: We estimated the methylation of the PAR2 promoter in both antral non-cancerous mucosa and cancer lesions in 94 patients with gastric cancer. We employed a methylation-specific PCR method. Results: Regarding the methylation ratio (MR) of antral-non-cancerous mucosa, no significant difference was despite among gender, age and Helicobacter pylori infection status, whereas MR increased rising inflammation scores. The MR of cancer lesions was significantly lower than that of antral non-cancerous mucosa. This finding was not dependent on tumor staging, but also histological classification. In venous invasion, lymph node metastasis, or peritoneal dissemination negative cases, this significant lower MR was also seen. Conclusion: The promoter methylation of PAR2 seems to be increased with a progression of chronic inflammation and has an inhibitory effect on carcinogenesis of the stomach.

Original languageEnglish
Pages (from-to)943-948
Number of pages6
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume22
Issue number6
DOIs
Publication statusPublished - 06-2007

Fingerprint

PAR-2 Receptor
Methylation
Stomach
Carcinogenesis
Mucous Membrane
Stomach Neoplasms
Neoplasms
Inflammation
Neoplasm Staging
Helicobacter Infections
DNA Methylation
Helicobacter pylori
Trypsin
Lymph Nodes
Neoplasm Metastasis
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Arisawa, Tomiyasu ; Tahara, Tomomitsu ; Shibata, Tomoyuki ; Nagasaka, Mitsuo ; Nakamura, Masakatsu ; Kamiya, Yoshio ; Fujita, Hiroshi ; Takagi, Tamaki ; Hasegawa, Shin ; Wang, Fang Yu ; Hirata, Ichiro ; Nakano, Hiroshi. / Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach. In: Journal of Gastroenterology and Hepatology (Australia). 2007 ; Vol. 22, No. 6. pp. 943-948.
@article{37d0a6cedd2149fb95727825ad626bb7,
title = "Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach",
abstract = "Background and Aim: Trypsin acting at protease-activated receptor 2 (PAR2) contributes to a progression of malignant tumors. An abnormal DNA methylation has been recognized as an important molecular mechanism for the genesis of various types of cancers. We attempted to clarify the relationship between the promoter methylation of PAR2 and gastric cancer. Method: We estimated the methylation of the PAR2 promoter in both antral non-cancerous mucosa and cancer lesions in 94 patients with gastric cancer. We employed a methylation-specific PCR method. Results: Regarding the methylation ratio (MR) of antral-non-cancerous mucosa, no significant difference was despite among gender, age and Helicobacter pylori infection status, whereas MR increased rising inflammation scores. The MR of cancer lesions was significantly lower than that of antral non-cancerous mucosa. This finding was not dependent on tumor staging, but also histological classification. In venous invasion, lymph node metastasis, or peritoneal dissemination negative cases, this significant lower MR was also seen. Conclusion: The promoter methylation of PAR2 seems to be increased with a progression of chronic inflammation and has an inhibitory effect on carcinogenesis of the stomach.",
author = "Tomiyasu Arisawa and Tomomitsu Tahara and Tomoyuki Shibata and Mitsuo Nagasaka and Masakatsu Nakamura and Yoshio Kamiya and Hiroshi Fujita and Tamaki Takagi and Shin Hasegawa and Wang, {Fang Yu} and Ichiro Hirata and Hiroshi Nakano",
year = "2007",
month = "6",
doi = "10.1111/j.1440-1746.2007.04847.x",
language = "English",
volume = "22",
pages = "943--948",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "6",

}

Arisawa, T, Tahara, T, Shibata, T, Nagasaka, M, Nakamura, M, Kamiya, Y, Fujita, H, Takagi, T, Hasegawa, S, Wang, FY, Hirata, I & Nakano, H 2007, 'Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach', Journal of Gastroenterology and Hepatology (Australia), vol. 22, no. 6, pp. 943-948. https://doi.org/10.1111/j.1440-1746.2007.04847.x

Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach. / Arisawa, Tomiyasu; Tahara, Tomomitsu; Shibata, Tomoyuki; Nagasaka, Mitsuo; Nakamura, Masakatsu; Kamiya, Yoshio; Fujita, Hiroshi; Takagi, Tamaki; Hasegawa, Shin; Wang, Fang Yu; Hirata, Ichiro; Nakano, Hiroshi.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 22, No. 6, 06.2007, p. 943-948.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Promoter hypomethylation of protease-activated receptor 2 associated with carcinogenesis in the stomach

AU - Arisawa, Tomiyasu

AU - Tahara, Tomomitsu

AU - Shibata, Tomoyuki

AU - Nagasaka, Mitsuo

AU - Nakamura, Masakatsu

AU - Kamiya, Yoshio

AU - Fujita, Hiroshi

AU - Takagi, Tamaki

AU - Hasegawa, Shin

AU - Wang, Fang Yu

AU - Hirata, Ichiro

AU - Nakano, Hiroshi

PY - 2007/6

Y1 - 2007/6

N2 - Background and Aim: Trypsin acting at protease-activated receptor 2 (PAR2) contributes to a progression of malignant tumors. An abnormal DNA methylation has been recognized as an important molecular mechanism for the genesis of various types of cancers. We attempted to clarify the relationship between the promoter methylation of PAR2 and gastric cancer. Method: We estimated the methylation of the PAR2 promoter in both antral non-cancerous mucosa and cancer lesions in 94 patients with gastric cancer. We employed a methylation-specific PCR method. Results: Regarding the methylation ratio (MR) of antral-non-cancerous mucosa, no significant difference was despite among gender, age and Helicobacter pylori infection status, whereas MR increased rising inflammation scores. The MR of cancer lesions was significantly lower than that of antral non-cancerous mucosa. This finding was not dependent on tumor staging, but also histological classification. In venous invasion, lymph node metastasis, or peritoneal dissemination negative cases, this significant lower MR was also seen. Conclusion: The promoter methylation of PAR2 seems to be increased with a progression of chronic inflammation and has an inhibitory effect on carcinogenesis of the stomach.

AB - Background and Aim: Trypsin acting at protease-activated receptor 2 (PAR2) contributes to a progression of malignant tumors. An abnormal DNA methylation has been recognized as an important molecular mechanism for the genesis of various types of cancers. We attempted to clarify the relationship between the promoter methylation of PAR2 and gastric cancer. Method: We estimated the methylation of the PAR2 promoter in both antral non-cancerous mucosa and cancer lesions in 94 patients with gastric cancer. We employed a methylation-specific PCR method. Results: Regarding the methylation ratio (MR) of antral-non-cancerous mucosa, no significant difference was despite among gender, age and Helicobacter pylori infection status, whereas MR increased rising inflammation scores. The MR of cancer lesions was significantly lower than that of antral non-cancerous mucosa. This finding was not dependent on tumor staging, but also histological classification. In venous invasion, lymph node metastasis, or peritoneal dissemination negative cases, this significant lower MR was also seen. Conclusion: The promoter methylation of PAR2 seems to be increased with a progression of chronic inflammation and has an inhibitory effect on carcinogenesis of the stomach.

UR - http://www.scopus.com/inward/record.url?scp=34250325945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250325945&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2007.04847.x

DO - 10.1111/j.1440-1746.2007.04847.x

M3 - Article

C2 - 17517084

AN - SCOPUS:34250325945

VL - 22

SP - 943

EP - 948

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 6

ER -